Stockscreener 앱 받기
5.57
1.64%
0.09
시간 외 거래:
5.57
전일 마감가:
$5.48
열려 있는:
$5.57
하루 거래량:
82,108
Relative Volume:
0.35
시가총액:
$310.28M
수익:
-
순이익/손실:
$-66.86M
주가수익비율:
-4.1567
EPS:
-1.34
순현금흐름:
$-58.82M
1주 성능:
-7.48%
1개월 성능:
-0.54%
6개월 성능:
+34.54%
1년 성능:
+154.34%
1일 변동 폭
$5.43
$5.725
1주일 범위
$5.32
$5.98
52주 변동 폭
$2.13
$7.77
디자인 테라 Stock (DSGN) Company Profile
명칭
Design Therapeutics Inc
전화
858-293-4900
주소
6005 HIDDEN VALLEY ROAD, CARLSBAD
DSGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| DSGN | 5.56 | 310.28M | 0 | -66.86M | -58.82M | -1.34 |
| VRTX | 450.34 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.15 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.68 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.25 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
디자인 테라 Stock (DSGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-05-04 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-06-10 | 개시 | Wedbush | Outperform |
| 2022-05-02 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-19 | 개시 | Goldman | Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-20 | 개시 | Piper Sandler | Overweight |
| 2021-04-20 | 개시 | SVB Leerink | Outperform |
모두보기
디자인 테라 주식(DSGN)의 최신 뉴스
Rakovina Therapeutics to present AI-driven brain cancer research at Neuro-Oncology Conference - Proactive Investors USA
(DSGN) Technical Data - Stock Traders Daily
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences - The Manila Times
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work - The Manila Times
Design Therapeutics (DSGN) to Present at Two Major Healthcare Conferences | DSGN Stock News - StockTitan
Design Therapeutics stock soars to 52-week high of $6.91 By Investing.com - Investing.com Canada
Design Therapeutics stock soars to 52-week high of $6.91 - Investing.com India
Design Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies - Nature.com
PTC data hot as Larimar, others advance in Friedreich’s ataxia - BioWorld Online
Long Term Trading Analysis for (DSGN) - Stock Traders Daily
Design Therapeutics Reports Strong Q3 and Pipeline Progress - TipRanks
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio - Marketscreener.com
Design Therapeutics Reports $254M Cash Runway, Advances Clinical Pipeline Through 2029 | DSGN Stock News - StockTitan
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - The Malaysian Reserve
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely - Yahoo Finance
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, - GlobeNewswire
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI - Yahoo Finance
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - Longview News-Journal
A new biotech, built around protein design, springs from David Baker’s lab - BioPharma Dive
Dr. Beyza Bulutoglu Celebrated for Dedication to the Field of Protein Engineering and Drug Discovery - 24-7 Press Release
Spinocerebellar Ataxias Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
Seaport Therapeutics Secures $225M for New Kind of Depression Drug - MedCity News
Nitric Oxide-Photodelivering Materials with Multiple Functionalities: From Rational Design to Therapeutic Applications - ACS Publications
Synthetic Nanoassemblies for Regulating Organelles: From Molecular Design to Precision Therapeutics - ACS Publications
Spinocerebellar Ataxias Pipeline Review 2024: Clinical Trials Update and Key Companies Involved by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc - Barchart
Enhancing De Novo Drug Design across Multiple Therapeutic Targets with CVAE Generative Models - ACS Publications
When (DSGN) Moves Investors should Listen - Stock Traders Daily
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index - Yahoo Finance
OSE Immunotherapeutics Presents New “Cis-Demasking” - GlobeNewswire
ElevateBio Announces Advancements of its Proprietary Lipid Nanoparticle (LNP) Delivery Platform with Liver Targeting and De-Targeting Potential - ForexTV.com
Glycomic Therapeutics Market Innovations, Challenges, - openPR
Dimensional Fund Advisors LP Has $271,000 Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Marshall Wace LLP Buys New Shares in Security National Financial Co. (NASDAQ:SNFCA) - Defense World
Marshall Wace LLP Cuts Stock Holdings in ARC Document Solutions, Inc. (NYSE:ARC) - Defense World
Marshall Wace LLP Invests $81,000 in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Marshall Wace LLP Reduces Holdings in TrueCar, Inc. (NASDAQ:TRUE) - Defense World
Squarepoint Ops LLC Has $294,000 Stock Holdings in Civeo Co. (NYSE:CVEO) - Defense World
Squarepoint Ops LLC Increases Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Squarepoint Ops LLC Lowers Stock Holdings in AerSale Co. (NASDAQ:ASLE) - Defense World
Cyrus Biotechnology Congratulates David Baker, 2024 Nobel Laureate in Chemistry and Cyrus Co-Founder - BioSpace
Tech News | American Press Technology News - Business Wire
Windtree Therapeutics Publishes SEISMiC Phase 2b Trial Design for Cardiac Treatment - MyChesCo
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design - Yahoo Finance
Cubist Systematic Strategies LLC Grows Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Relay Therapeutics to Lay Off 10% of Workforce - BioSpace
Point72 Asset Management L.P. Buys 397,285 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Point72 Asset Management L.P. Has $3.32 Million Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - MarketBeat
Point72 Asset Management L.P. Raises Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Almitas Capital LLC Has $4.20 Million Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
디자인 테라 (DSGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):